\r\n\r\nAbstract #269 \"Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)”\r\n\r\n \r\n\r\nRead more in the online publication in NEJM here.\r\n\r\n"}}}; dataLayer.push( dataLayer_content );

Skip to Content

februar 2021

Promising results for lenvatinib in combination with pembrolizumab or everolimus in 1L advanced renal cell carcinoma

The results of the phase 3 CLEAR-study in 1L treatment of patients with advanced renal cell carcinoma show that lenvatinib in combination with pembrolizumab or everolimus improve progression-free survival and response rate compared to sunitinib, whereas the combination of lenvatinib and pembrolizumab also significantly improves survival.